Visão geral da empresa
A clinical-stage biotechnology enterprise, Coya Therapeutics, Inc. focuses on developing proprietary therapies designed to enhance the functional capacity of regulatory T cells, utilizing modalities such as Treg-enhancing biologics and Treg-derived exosomes. The company operates within the healthcare sector, specifically the biotechnology industry, positioning itself as a specialized developer of therapeutic assets rather than a diversified conglomerate. As of the latest data, the organization maintains a market capitalization of $106.26M, generates annual revenue of $7.95M, and employs a workforce of 8 individuals. These financial metrics indicate that Coya is a micro-cap entity with a valuation significantly higher than its current revenue base, suggesting the market is pricing in substantial future potential or clinical milestones rather than current operational profitability. The small employee count relative to the market cap further highlights the asset-light nature of the company's current business model, which relies heavily on intellectual property and research and development expenditures.
Saúde financeira
The company reported a revenue of $7.95M over the trailing twelve months, yet this income was insufficient to cover operating costs, resulting in a net income loss of $-21,226,108 and an EBITDA of $-20,238,262. The substantial disparity between the positive revenue figure and the deeply negative net income reveals a cost structure characterized by intense spending on research, clinical trials, and operational overhead that far exceeds current sales generation. Free cash flow stands at $-4,613,089, indicating that the company is burning cash at a rate that requires continuous external financing or the utilization of existing reserves to sustain operations. Profitability metrics are severely impacted by these costs, with a gross margin of -110.6%, an operating margin of -107.5%, and a profit margin of -267.1%, all of which reflect the typical pre-commercial stage of a biotechnology firm where R&D expenses exceed gross revenues. Despite these losses, the balance sheet retains $46.82M in cash against $0 in debt, creating a distinct lack of leverage that provides a buffer for future R&D investments. The current ratio of 8.51 demonstrates robust short-term liquidity, as the company holds significantly more current assets than current liabilities, ensuring it can meet its immediate financial obligations without distress. Furthermore, the return on equity is -51.4% and the return on assets is -26.9%, metrics that indicate management is currently utilizing capital to generate negative returns, a common scenario for clinical-stage firms before a product achieves commercial approval.
Avaliação de valorização
Valuation multiples for Coya Therapeutics reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -3.92, implying that the market does not value the stock based on current earnings but rather on future expectations of profitability that have not yet been realized. The price-to-book ratio is 2.20, suggesting that the market values the company at more than double its book value, a premium that likely encompasses the potential value of its intellectual property and clinical pipeline assets. Alternative valuation metrics such as the price-to-sales ratio of 13.37 and an EV/EBITDA of -2.94 further underscore that investors are paying a significant multiple for revenue without corresponding current earnings, highlighting the speculative nature of the investment. In terms of trading range, the stock has a 52-week high of $7.75 and a 52-week low of $3.71; assuming the current price is near the recent market activity, the valuation sits below the yearly peak but above the yearly trough, exhibiting typical volatility for small-cap biotech securities. The beta of 0.52 indicates that the stock's price volatility is less than half that of the broader market, which is somewhat counterintuitive for a small-cap biotech firm but suggests that recent trading patterns have dampened its correlation with general market swings.
Growth & Income
Coya Therapeutics experienced a revenue growth rate of 202768.8% year over year, while earnings growth is N/A due to the company's continued losses, indicating that top-line expansion is occurring despite the absence of profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, any earnings generated in the future would be reinvested into the business rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechs, where capital is directed toward advancing drug candidates through clinical trials rather than rewarding investors with income. The overall growth and income profile is defined by explosive revenue expansion coupled with a complete lack of dividend income, creating a high-risk, high-reward scenario dependent entirely on the successful development of its therapeutic pipeline.